Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Cancer Research on Prevention and Treatment》 2010-03
Add to Favorite Get Latest Update

Effect of Rosiglitazone on Expression of VEGF in Liver Cancer Cell Line SMMC-7721

ZHANG Meng,PENG Li,MIAO Zhan-jun,XU Zhuo,WANG Shun-xiang,TANG Rui-feng,ZHANG Feng-rui,WANG Shi-jieDepartment of Hepatobiliary Surgery,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China  
Objective To study the effects of rosiglitazone ligands of peroxisome proliferator-activated receptor-γ(PPAR-γ) on the expression of VEGF in hepatocellular carcinoma cell line SMMC-7721,in vitro and to reveal the related molecular mechanisms.Methods After treatment with different concentration of rosiglitazone (0,0.1,1,10 and 100μmol/L) for different time(24h,48h and 72h),the expressions of VEGF,PTEN,Akt1/2 and P-Akt1 were detected by western blot.Results Rosiglitazone could significantly inhibit the expression of VEGF in SMMC-7721 cells and have both time-dependent and concentration-dependent manner(P0.05).Rosiglitazone increased the expression of PTEN remarkably in both time-dependent and concentration-dependent manner(P0.05),but has no influence on the expression of Akt1/2 and P-Akt1.Conclusion This study suggested that activation of PPARγ by rosiglitazone can inhibit the expression of VEGF,which may be through the upregulation the expression level of PTEN while not directly relying on PI3K/Akt.
【Fund】: 河北省高校强势特色学科资助项目;; 河北省卫生厅资助课题(06142)
【CateGory Index】: R735.7
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved